• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Defiance Launches ZYN: 2X Long ETF for Philip Morris International Inc.

    9/4/25 9:59:28 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email

    MIAMI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Long PM ETF (Ticker: ZYN). This fund provides investors with amplified 2X daily exposure to the performance of Philip Morris International Inc. (NYSE:PM), enabling retail investors to participate in the growth of a leading innovator without the need for a margin account.

    ZYN seeks to deliver daily investment results, before fees and expenses, of 200% of the daily performance of Philip Morris International Inc.. The Fund utilizes derivatives such as swaps and options to achieve its leveraged objectives, offering precise exposure to this issuer.

    Why Philip Morris International?

    Philip Morris International (NYSE:PM) is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products, and associated devices.

    With its flagship IQOS platform and a growing portfolio of reduced-risk products, the company is pursuing a future beyond smoking by transitioning adult smokers toward less harmful alternatives.

    An investment in ZYN is not an investment in Philip Morris International Inc..

    The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage, and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. For periods longer than a single day, the Fund will lose money if the Underlying Security's performance is flat, and it is possible that the Fund will lose money even if the Underlying Security's performance increases over a period longer than a single day. An investor could lose the full principal value of his/her investment within a single day.

    About Defiance

    Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs. Our first-mover leveraged single-stock ETFs empower investors to take amplified positions in high-growth companies, providing precise leverage exposure without the need to open a margin account.

    IMPORTANT DISCLOSURES

    The Fund's investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read carefully before investing. A hard copy of the prospectuses can be requested by calling 833.333.9383.

    Defiance ETFs LLC is the ETF sponsor. The Fund's investment adviser is Tidal Investments, LLC ("Tidal" or the "Adviser").

    Investing involves risk. Principal loss is possible. As an ETF, the fund may trade at a premium or discount to NAV. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. A portfolio concentrated in a single industry or country may be subject to a higher degree of risk.

    There is no guarantee that the Fund's investment strategy will be properly implemented, and an investor may lose some or all of its investment.

    Underlying Security Risk. The underlying security is subject to many risks that can negatively impact the Fund.

    Underlying Securities Trading Risk. The trading prices of PM may be highly volatile and subject to wide fluctuations in response to various factors.

    Underlying Securities Performance Risk. Philip Morris International Inc. may fail to meet expectations, which could cause its share price to decline.

    Consumer Products Industry Risk. The tobacco and reduced-risk product industry faces regulatory pressures, litigation risks, and evolving consumer preferences.

    Derivatives Risks. Derivative investments may not perfectly track the underlying security and can magnify losses.

    Swap Agreements and Options Contracts. These instruments involve specialized risks that can prevent the Fund from achieving its objectives.

    Leverage Risk. Leverage increases risk of loss and volatility in Fund value.

    Compounding Risk. The Fund has a single-day investment objective, and compounding can cause multi-day returns to diverge significantly from the stated daily target.

    High Portfolio Turnover Risk. Frequent trading may increase costs and tax liabilities.

    Non-Diversification & Single Issuer Risk. The Fund invests primarily in a single issuer, making it more volatile than diversified funds.

    New Fund Risk. The Fund has no operating history, limiting performance assessment.

    Brokerage commissions may be charged on trades.

    Distributed by Foreside Fund Services, LLC.

    David Hanono

    [email protected]

    833.333.9383

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eed021d4-f9bb-4dad-81dc-332c74c90027



    Get the next $PM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy → Hold
    Jefferies
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    More analyst ratings

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Philip Morris International downgraded by Jefferies with a new price target

    Jefferies downgraded Philip Morris International from Buy to Hold and set a new price target of $180.00

    1/20/26 9:10:49 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, and Group Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2026 Consumer Analyst Group of New York (CAGNY) Conference at approximately 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The presentation will cover: How a transformed PMI is leading the industry in an evolving operating environment; The success and future opportu

    2/18/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International to Present at 2026 CAGNY Conference

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast of a presentation by Jacek Olczak, Group CEO PMI, and Emmanuel Babeau, Group Chief Financial Officer, at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 18, 2026, at 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading internati

    2/11/26 8:17:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

    Delivers Full Year 2025 Reported Diluted EPS of $7.26 compared to $4.52 in 2024 and Adjusted Diluted EPS of $7.54, Representing Growth of 14.8%, and 14.2% on a Currency-Neutral Basis; Provides 2026 - 2028 Growth Targets Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 fourth quarter results.1 "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke-free business, and very good operating margin expansion," said Jacek Olczak, Group CEO PMI. "With excellent results in 2024 and 2025, we have delivered our three-year CA

    2/6/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group Chief Financial Officer Babeau Emmanuel covered exercise/tax liability with 2,228 shares and sold $6,138,418 worth of shares (33,800 units at $181.61), decreasing direct ownership by 18% to 164,463 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/20/26 4:01:45 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Group Controller Dobrowolski Reginaldo covered exercise/tax liability with 250 shares and sold $1,100,880 worth of shares (6,000 units at $183.48), decreasing direct ownership by 20% to 21,182 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/20/26 4:01:38 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    CEO PMI U.S. Kennedy Stacey covered exercise/tax liability with 4,324 shares and sold $2,627,916 worth of shares (14,350 units at $183.13), decreasing direct ownership by 29% to 45,301 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/20/26 4:01:20 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    SEC Filings

    View All

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    2/18/26 10:04:09 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    2/18/26 7:04:54 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-3ASR filed by Philip Morris International Inc

    S-3ASR - Philip Morris International Inc. (0001413329) (Filer)

    2/6/26 4:10:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

    The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

    1/20/26 5:03:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, and Group Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2026 Consumer Analyst Group of New York (CAGNY) Conference at approximately 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The presentation will cover: How a transformed PMI is leading the industry in an evolving operating environment; The success and future opportu

    2/18/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

    Delivers Full Year 2025 Reported Diluted EPS of $7.26 compared to $4.52 in 2024 and Adjusted Diluted EPS of $7.54, Representing Growth of 14.8%, and 14.2% on a Currency-Neutral Basis; Provides 2026 - 2028 Growth Targets Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 fourth quarter results.1 "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke-free business, and very good operating margin expansion," said Jacek Olczak, Group CEO PMI. "With excellent results in 2024 and 2025, we have delivered our three-year CA

    2/6/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on January 14, 2026, to shareholders of record as of December 26, 2025. The ex-dividend date is December 26, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio prim

    12/12/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care